ELDN Profile
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with autoimmune diseases, amyotrophic lateral sclerosis (ALS), and those requiring organ or cell-based transplants. The company's primary focus is on advancing its lead product candidate, AT-1501, a humanized monoclonal antibody designed to target CD40 Ligand, a molecule expressed on the surface of immune system T cells.
AT-1501 is currently undergoing Phase 2a clinical trials for the treatment of ALS, a progressive neurodegenerative disorder. Additionally, the drug is in Phase 2 clinical trials for islet cell transplantation, aimed at improving outcomes for patients with type 1 diabetes. These trials represent Eledon's commitment to addressing significant medical needs through targeted and potentially transformative therapies.
Previously known as Novus Therapeutics, Inc., the company rebranded to Eledon Pharmaceuticals, Inc. in January 2021 to better reflect its focus on developing advanced therapeutic solutions. Eledon Pharmaceuticals is headquartered in Irvine, California, and has positioned itself at the forefront of biopharmaceutical innovation with a pipeline focused on high-impact therapeutic areas.
Founded with the aim of addressing challenging medical conditions, Eledon Pharmaceuticals leverages its expertise in immunology and transplantation to drive its research and development efforts. The company's strategic focus on advancing AT-1501 underscores its commitment to improving patient outcomes and addressing unmet medical needs in the fields of autoimmune disease, ALS, and transplantation.
|
